乳腺癌新辅助内分泌治疗对ER、PR、C—erbB-2表达的影响

目的探讨60岁以上绝经后期乳腺癌患者术前行内分泌治疗对ER、PR、C—erbB-2表达的影响及其意义。方法本组36例每日口服三苯氧胺两次，一次10mg，疗程60～90d。在新辅助内分泌治疗前、后均行ER、PR、C—erbB-2测定。结果36例ER、PR阴性表达率在新辅助内分泌治疗前分别为16．78％、11．11％；治疗后分别为50％、33．33％差异有统计学意义（P〈0．05）。C—erbB-2在新辅助内分泌治疗前后表达率分别为13．89％、16．67％，差异无统计学意义（P〉0．05）。结论单用三苯氧胺可下调ER、PR的表达，抑制肿瘤生长，使部分病例获得缓解。

The effects of neoadjuvant endocrine therapy on expressions of ER, PR and C-erbB-2 in breast cancer patients

Objective To explore the effects of preoperative neoadjuvant endocrine therapy on expression and significance of ER, PR, C-erbB-2 in pestmenopause breast cancer patients over 60 years old. Methods 36 patients were treated with endrocrine therapy by oral tamoxifen for 60 ～ 90 days, and the expression of ER, PR and C-erbB-2 was examined before and after the endrocrine therapy. Results In 36 patients the negative expres-sion rate of ER, PR was 16.78% and 11.11% respectively before the endrocrine therapy, compared to 50% and 33.33% after the endrocrine therapy. There was significant difference(P<0.05). The expression of C-erbB-2 was 13.8% and 16.67% before and after the endrocrine therapy, and there was no significant difference between the two figures. Conclusions The neoadjuvant endocrine therapy by tamoxifen alone can down-regulate the ex-pression of ER, PR, and can inhibit tumor growth. Some patients may get partially relieved.